Cargando…

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Paré, L, Marcuello, E, Altés, A, del Río, E, Sedano, L, Salazar, J, Cortés, A, Barnadas, A, Baiget, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676547/ http://dx.doi.org/10.1038/sj.bjc.6605004

Ejemplares similares

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
por: Paré, L, et al.
Publicado: (2008)

A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
por: Marcuello, E, et al.
Publicado: (2011)

Hyperammonemic encephalopathy in a patient receiving fluorouracil/oxaliplatin chemotherapy
por: Ihoriya, Hiromi, et al.
Publicado: (2018)

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
por: Marcuello, E, et al.
Publicado: (2004)

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
por: Sobrero, A, et al.
Publicado: (2005)

Corrigendum to “Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents”
por: Dos Santos-Júnior, Amilton, et al.
Publicado: (2017)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Corrigendum to “Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy”
por: Moastafa, Tarek M., et al.
Publicado: (2015)

Synergic effect between 5-fluorouracil and celecoxib on hypoxic gastric cancer cells
por: Zhang, Xiao-Qian, et al.
Publicado: (2021)

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
por: Gravalos, Cristina, et al.
Publicado: (2012)

Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
por: Zhao, Yang, et al.
Publicado: (2021)

Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer
por: Moon, Joon Ho, et al.
Publicado: (2007)

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
por: Fischel, J-L, et al.
Publicado: (2001)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]
por: Reck, M., et al.
Publicado: (2021)

In situ Delivery of Thermosensitive Gel-Mediated 5-Fluorouracil Microemulsion for the Treatment of Colorectal Cancer [Corrigendum]
Publicado: (2020)

Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel-7402/5-fluorouracil cells
por: Ling, Sunbin, et al.
Publicado: (2022)

Corrigendum: Analgesic effect of AG490, a Janus kinase inhibitor, on oxaliplatin-induced acute neuropathic pain
Publicado: (2019)

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
por: Santini, D, et al.
Publicado: (2006)

Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma
por: Kataoka, Junro, et al.
Publicado: (2017)

A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer
por: Wang, Qinchuan, et al.
Publicado: (2020)

Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pancreatic Adenocarcinoma
por: Dacie, Ruth, et al.
Publicado: (2020)

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
por: Banna, G.L., et al.
Publicado: (2021)

Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
por: Neri, B, et al.
Publicado: (2007)

Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer
por: Ikezawa, Kenji, et al.
Publicado: (2021)

CORRIGENDUM to “Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?”
Publicado: (2021)

Fluorouracil/oxaliplatin: Coronary vasospasm and neutropenia: case report
Publicado: (2019)

Fluorouracil/oxaliplatin/panitumumab: Lack of efficacy: case report
Publicado: (2022)

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
por: Chau, I, et al.
Publicado: (2001)

Combined antitumor effects of P-5m octapeptide and 5- fluorouracil on a murine model of H22 hepatoma ascites
por: Han, Xiao, et al.
Publicado: (2019)

Downregulation of miR-486-5p Enhances the Anti-Tumor Effect of 5-Fluorouracil on Pancreatic Cancer Cells [Corrigendum]
Publicado: (2020)

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
por: Dawson, S-J, et al.
Publicado: (2010)

Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL induced apoptosis in vitro and in vivo
por: Oikonomou, E, et al.
Publicado: (2007)

Corrigendum to “Combinatorial Cytotoxic Effects of Gelam Honey and 5-Fluorouracil against Human Adenocarcinoma Colon Cancer HT-29 Cells In Vitro”
por: T-Johari, Syed Ahmad Tajudin, et al.
Publicado: (2019)

S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
por: Kim, S Y, et al.
Publicado: (2013)

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil
por: Chen, C-C, et al.
Publicado: (2007)

Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs
por: OCHIAI, TAKUMI, et al.
Publicado: (2013)

The Drug Efficacy and Adverse Reactions in a Mouse Model of Oral Squamous Cell Carcinoma Treated with Oxaliplatin at Different Time Points During a Day [Corrigendum]
Publicado: (2020)

Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jt9f7qn3ggvo7ebj2pk61acu6s